Identification of 6-amino-1H-pyrazolo[3,4-d]pyrimidines with in vivo efficacy against visceral leishmaniasis

Michael G. Thomas, Manu De Rycker, Myriam Ajakane, Sabrinia D. Crouch, Lorna Campbell, Alain Daugan, Gloria Fra, César Guerrero, Claire J. Mackenzie, Lorna MacLean, Sujatha Manthri, Franck Martin, Suzanne Norval, Maria Osuna-Cabello, Jennifer Riley, Yoko Shishikura, Juan Miguel-Siles, Frederick R. C. Simeons, Laste Stojanovski, John ThomasStephen Thompson, Raul F. Velasco, Jose M. Fiandor, Paul G. Wyatt, Kevin D. Read, Ian H. Gilbert (Lead / Corresponding author), Timothy J. Miles (Lead / Corresponding author)

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)
87 Downloads (Pure)


Visceral leishmaniasis (VL) affects millions of people across the world, largely in developing nations. It is fatal if left untreated and the current treatments are inadequate. As such, there is an urgent need for new, improved medicines. In this paper, we describe the identification of a 6-amino-N-(piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidine scaffold and its optimization to give compounds which showed efficacy when orally dosed in a mouse model of VL.
Original languageEnglish
Pages (from-to)1168-1177
Number of pages10
JournalRSC Medicinal Chemistry
Issue number10
Early online date6 Aug 2020
Publication statusPublished - 21 Oct 2020

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Organic Chemistry
  • Drug Discovery
  • Pharmaceutical Science
  • Pharmacology


Dive into the research topics of 'Identification of 6-amino-1H-pyrazolo[3,4-d]pyrimidines with in vivo efficacy against visceral leishmaniasis'. Together they form a unique fingerprint.

Cite this